The 5 Largest IPOs in Biopharma History

Why It Matters

The comeback signals that capital markets are once again willing to fund high‑risk, high‑reward biopharma ventures, accelerating development pipelines in obesity, mRNA, and cell‑therapy spaces. Investors and companies alike can leverage this liquidity to scale breakthroughs that could reshape therapeutic landscapes.

Key Takeaways

• Kailera's $625 M IPO tops biopharma history.
• Obesity market projected $200 B by 2030, driving investor interest.
• Moderna's $604 M IPO; valuation now $21 B post‑COVID.
• Sana raised $587.5 M IPO to fund cell‑engineering platform.
• 2026 Q1 saw ten biotech IPOs, eclipsing 2025 class.

Pulse Analysis

The resurgence of biopharma IPOs in 2026 marks a turning point after a pandemic‑induced funding slowdown. Kailera Therapeutics’ $625 million offering not only set a new benchmark but also highlighted the sector’s pivot toward obesity therapeutics, a market projected to reach $200 billion by 2030. Investors are gravitating toward assets that promise both clinical impact and sizable revenue streams, and the sheer scale of Kailera’s raise signals confidence in the commercial viability of GLP‑1/GIP dual agonists and oral peptide platforms.

Comparisons with earlier marquee listings illustrate how the capital landscape has evolved. Moderna’s 2018 IPO of $604 million propelled the mRNA pioneer into a $7.5 billion market cap, yet post‑COVID earnings volatility has trimmed its valuation to roughly $21 billion. Sana Biotechnology leveraged a $587.5 million IPO to bankroll its cell‑engineering platform, while Acelyrin and Recursion secured $540 million and $436 million respectively, betting on antibody mimetics and AI‑driven drug discovery. These companies faced mixed outcomes—Acelyrin’s lead asset faltered, prompting strategic mergers, whereas Recursion’s AI model continues to attract partnerships with majors like Sanofi and Roche.

For investors, the renewed IPO activity offers a dual‑edged opportunity. Fresh capital can accelerate late‑stage trials and expand pipelines, but the heightened valuations demand rigorous due diligence, especially as many firms still rely on speculative assets. Market watchers should monitor upcoming obesity licensing deals, the pipeline progression of mRNA and cell‑therapy candidates, and the broader macro‑economic backdrop that could influence future public offerings. The next wave of biopharma IPOs will likely be defined by how effectively companies translate their scientific promise into sustainable commercial products.